Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 3Phase 1 2

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 1Genitourinary 1Dermatologic 1Classical hematology 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Cytopenia 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × HuMax-IL8 × Clear all
NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Bristol-Myers Squibb

Phase 1/2 Completed
281 enrolled 44 charts
Dermatologic

Melanoma, Neoplasms

NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

NCT03689699 2025-04-29

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Columbia University

Phase 1/2 Active not recruiting
59 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡